• 1
    Bachmann F (1987) Fibrinolysis. In Thrombosis and Haemostasis. (VerstraeteM, ed), pp. 227265. Leuven University Press, Leuven, the Netherlands.
  • 2
    Tsirka SE (2002) Tissue plasminogen activator as a modulator of neuronal survival and function. Biochem Soc Trans 30, 222225.
  • 3
    Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, Vivien D & Buisson A (2001) The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 7, 5964.
  • 4
    Rogove AD, Siao C, Keyt B, Strickland S & Tsirka SE (1999) Activation of microglia reveals a non-proteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 112, 40074016.
  • 5
    Waltz DA, Natkin LR, Fujita RM, Wei Y & Chapman HA (1997) Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 100, 5867.
  • 6
    Czekay RP & Loskutoff DJ (2004) Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp Biol Med (Maywood) 229, 10901096.
  • 7
    Genton C, Kruithof EK & Schleuning WD (1987) Phorbol ester induces the biosynthesis of glycosylated and nonglycosylated plasminogen activator inhibitor 2 in high excess over urokinase-type plasminogen activator in human U-937 lymphoma cells. J Cell Biol 104, 705712.
  • 8
    Kawano T, Morimoto K & Uemura Y (1970) Partial purification and properties of urokinase inhibitor from human placenta. J Biochem (Tokyo) 67, 333342.
  • 9
    Wun TC & Reich E (1987) An inhibitor of plasminogen activation from human placenta. Purification and characterization. J Biol Chem 262, 36463653.
  • 10
    Kruithof EK, Tran-Thang C, Gudinchet A, Hauert J, Nicoloso G, Genton C, Welti H & Bachmann F (1987) Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 69, 460466.
  • 11
    Belin D, Wohlwend A, Schleuning WD, Kruithof EK & Vassalli JD (1989) Facultative polypeptide translocation allows a single mRNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor 2. EMBO J 8, 32873294.
  • 12
    von Heijne G, Liljestrom P, Mikus P, Andersson H & Ny T (1991) The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem 266, 1524015243.
  • 13
    Pemberton PA, Tipton AR, Pavloff N, Smith J, Erickson JR, Mouchabeck ZM & Kiefer MC (1997) Maspin is an intracellular serpin that partitions into secretory vesicles and is present at the cell surface. J Histochem Cytochem 45, 16971706.
  • 14
    Medcalf RL, Kruithof EK & Schleuning WD (1988) Plasminogen activator inhibitor 1 and 2 are tumor necrosis factor/cachectin-responsive genes. J Exp Med 168, 751759.
  • 15
    Remold-O'Donnell E (1993) The ovalbumin family of serpin proteins. FEBS Lett 315, 105108.
  • 16
    Jensen PH, Schuler E, Woodrow G, Richardson M, Goss N, Hojrup P, Petersen TE & Rasmussen LK (1994) A unique interhelical insertion in plasminogen activator inhibitor-2 contains three glutamines, Gln83, Gln84, Gln86, essential for transglutaminase-mediated cross-linking. J Biol Chem 269, 1539415398.
  • 17
    Jensen PH, Lorand L, Ebbesen P & Gliemann J (1993) Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. Eur J Biochem 214, 141146.
  • 18
    Ritchie H, Lawrie LC, Crombie PW, Mosesson MW & Booth NA (2000) Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen). J Biol Chem 275, 2491524920.
  • 19
    Jensen PH, Jensen TG, Laug WE, Hager H, Gliemann J & Pepinsky B (1996) The exon 3 encoded sequence of the intracellular serine proteinase inhibitor plasminogen activator inhibitor 2 is a protein binding domain. J Biol Chem 271, 2689226899.
  • 20
    Darnell GA, Antalis TM, Johnstone RW, Stringer BW, Ogbourne SM, Harrich D & Suhrbier A (2003) Inhibition of retinoblastoma protein degradation by interaction with the serpin plasminogen activator inhibitor 2 via a novel consensus motif. Mol Cell Biol 23, 65206532.
  • 21
    Fan J, Zhang YQ, Li P, Hou M, Tan L, Wang X & Zhu YS (2004) Interaction of plasminogen activator inhibitor-2 and proteasome subunit, beta type 1. Acta Biochim Biophys Sin (Shanghai) 36, 4246.
  • 22
    Lomas DA & Carrell RW (2002) Serpinopathies and the conformational dementias. Nat Rev Genet 3, 759768.
  • 23
    Mikus P & Ny T (1996) Intracellular polymerization of the serpin plasminogen activator inhibitor type 2. J Biol Chem 271, 1004810053.
  • 24
    Wilczynska M, Lobov S & Ny T (2003) The spontaneous polymerization of plasminogen activator inhibitor type-2 and Z-antitrypsin are due to different molecular aberrations. FEBS Lett 537, 1116.
  • 25
    Lobov S, Wilczynska M, Bergstrom F, Johansson LB & Ny T (2004) Structural bases of the redox-dependent conformational switch in the serpin PAI-2. J Mol Biol 344, 13591368.
  • 26
    Kruithof EK, Baker MS & Bunn CL (1995) Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 86, 40074024.
  • 27
    Sharon R, Abramovitz R & Miskin R (2002) Plasminogen mRNA induction in the mouse brain after kainate excitation: codistribution with plasminogen activator inhibitor-2 (PAI-2) mRNA. Brain Res Mol Brain Res 104, 170175.
  • 28
    Scherrer A, Kruithof EK & Grob JP (1991) Plasminogen activator inhibitor-2 in patients with monocytic leukemia. Leukemia 5, 479486.
  • 29
    Hofmann GE, Glatstein I, Schatz F, Heller D & Deligdisch L (1994) Immunohistochemical localization of urokinase-type plasminogen activator and the plasminogen activator inhibitors 1 and 2 in early human implantation sites. Am J Obstet Gynecol 170, 671676.
  • 30
    Black S, Yu, H, Lee J, Sachchithananthan M & Medcalf RL (2001) Physiologic concentrations of magnesium and placental apoptosis: prevention by antioxidants. Obstet Gynecol 98, 319324.
  • 31
    Radtke KP, Wenz KH & Heimburger N (1990) Isolation of plasminogen activator inhibitor-2 (PAI-2) from human placenta. Evidence for vitronectin/PAI-2 complexes in human placenta extract. Biol Chem Hoppe Seyler 371, 11191127.
  • 32
    Dougherty KM, Pearson JM, Yang AY, Westrick RJ, Baker MS & Ginsburg D (1999) The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival. Proc Natl Acad Sci USA 96, 686691.
  • 33
    Belin D (1993) Biology and facultative secretion of plasminogen activator inhibitor-2. Thromb Haemost 70, 144147.
  • 34
    Hibino T, Matsuda Y, Takahashi T & Goetinck PF (1999) Suppression of keratinocyte proliferation by plasminogen activator inhibitor-2. J Invest Dermatol 112, 8590.
  • 35
    Risse BC, Chung NM, Baker MS & Jensen PJ (2000) Evidence for intracellular cleavage of plasminogen activator inhibitor type 2 (PAI-2) in normal epidermal keratinocytes. J Cell Physiol 182, 281289.
  • 36
    Zhou HM, Bolon I, Nichols A, Wohlwend A & Vassalli JD (2001) Overexpression of plasminogen activator inhibitor type 2 in basal keratinocytes enhances papilloma formation in transgenic mice. Cancer Res 61, 970976.
  • 37
    Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T & Matsushima K (2000) Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 96, 25842591.
  • 38
    Schwartz BS & Bradshaw JD (1992) Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. Correlation with production of the protein. J Biol Chem 267, 70897094.
  • 39
    Schleuning WD, Medcalf RL, Hession C, Rothenbuhler R, Shaw A & Kruithof EK (1987) Plasminogen activator inhibitor 2: regulation of gene transcription during phorbol ester-mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 7, 45644567.
  • 40
    Gross TJ & Sitrin RG (1990) The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2. J Immunol 144, 18731879.
  • 41
    Ragno P, Montuori N, Vassalli JD & Rossi G (1993) Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism of urokinase activity. FEBS Lett 323, 279284.
  • 42
    Katsikis J, Yu, H, Maurer F & Medcalf R (2000) The molecular basis for the aberrant production of plasminogen activator inhibitor type 2 in THP-1 monocytes. Thromb Haemost 84, 468473.
  • 43
    Yu H, Maurer F & Medcalf RL (2002) Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation. Blood 99, 28102818.
  • 44
    Swartz JM, Bystrom J, Dyer KD, Nitto T, Wynn TA & Rosenberg HF (2004) Plasminogen activator inhibitor-2 (PAI-2) in eosinophilic leukocytes. J Leukoc Biol 76, 812819.
  • 45
    Chuang TL & Schleef RR (1999) Identification of a nuclear targeting domain in the insertion between helices C and D in protease inhibitor-10. J Biol Chem 274, 1119411198.
  • 46
    Bird CH, Blink EJ, Hirst CE, Buzza MS, Steele PM, Sun J, Jans DA & Bird PI (2001) Nucleocytoplasmic distribution of the ovalbumin serpin PI-9 requires a nonconventional nuclear import pathway and the export factor Crm1. Mol Cell Biol 21, 53965407.
  • 47
    Marioni G, Blandamura S, Giacomelli L, Calgaro N, Segato P, Leo G, Fischetto D, Staffieri A & de Filippis C (2005) Nuclear expression of maspin is associated with a lower recurrence rate and a longer disease-free interval after surgery for squamous cell carcinoma of the larynx. Histopathology 46, 576582.
  • 48
    Harbour JW & Dean DC (2000) Rb function in cell-cycle regulation and apoptosis. Nat Cell Biol 2, E65E67.
  • 49
    Hasina R, Hulett K, Bicciato S, Di Bello C, Petruzzelli GJ & Lingen MW (2003) Plasminogen activator inhibitor-2: a molecular biomarker for head and neck cancer progression. Cancer Res 63, 555559.
  • 50
    Borstnar S, Vrhovec I, Svetic B & Cufer T (2002) Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. Clin Breast Cancer 3, 138146.
  • 51
    Yoshino H, Endo Y, Watanabe Y & Sasaki T (1998) Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis. Br J Cancer 78, 833839.
  • 52
    Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, Klijn JG & Kramer MD (1995) Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 55, 14231427.
  • 53
    Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, O'Higgins N & Duffy MJ (1997) Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer 76, 622627.
  • 54
    Mueller BM, Yu, YB & Laug WE (1995) Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 92, 205209.
  • 55
    Laug WE, Cao XR, Yu YB, Shimada H & Kruithof EK (1993) Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 53, 60516057.
  • 56
    Al-Ejeh F, Croucher D & Ranson M (2004) Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp Cell Res 297, 259271.
  • 57
    Allen BJ, Tian Z, Rizvi SM, Li Y & Ranson M (2003) Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. Br J Cancer 88, 944950.
  • 58
    Ranson M, Tian Z, Andronicos NM, Rizvi S & Allen BJ (2002) In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells. Breast Cancer Res Treat 71, 149159.
  • 59
    Allen BJ, Rizvi S, Li Y, Tian Z & Ranson M (2001) In vitro and preclinical targeted alpha therapy for melanoma, breast, prostate and colorectal cancers. Crit Rev Oncol Hematol 39, 139146.
  • 60
    Silverman GA, Jockel JI, Domer PH, Mohr RM, Taillon-Miller P & Korsmeyer SJ (1991) Yeast artificial chromosome cloning of a two-megabase-size contig within chromosomal band 18q21 establishes physical linkage between BCL2 and plasminogen activator inhibitor type-2. Genomics 9, 219228.
  • 61
    Weiss LM, Warnke RA, Sklar J & Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317, 11851189.
  • 62
    Kumar S & Baglioni C (1991) Protection from tumor necrosis factor-mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 266, 2096020964.
  • 63
    Dickinson JL, Bates EJ, Ferrante A & Antalis TM (1995) Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function. J Biol Chem 270, 2789427904.
  • 64
    Jensen PH, Cressey LI, Gjertsen BT, Madsen P, Mellgren G, Hokland P, Gliemann J, Doskeland SO, Lanotte M & Vintermyr OK (1994) Cleaved intracellular plasminogen activator inhibitor 2 in human myeloleukaemia cells is a marker of apoptosis. Br J Cancer 70, 834840.
  • 65
    Antalis TM, La Linn M, Donnan K, Mateo L, Gardner J, Dickinson JL, Buttigieg K & Suhrbier A (1998) The serine proteinase inhibitor (serpin) plasminogen activation inhibitor type 2 protects against viral cytopathic effects by constitutive interferon alpha/beta priming. J Exp Med 187, 17991811.
  • 66
    Shafren DR, Gardner J, Mann VH, Antalis TM & Suhrbier A (1999) Picornavirus receptor down-regulation by plasminogen activator inhibitor type 2. J Virol 73, 71937198.
  • 67
    Dear AE & Medcalf RL (1995) The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 9, 321330.
  • 68
    Antalis TM, Clark MA, Barnes T, Lehrbach PR, Devine PL, Schevzov G, Goss NH, Stephens RW & Tolstoshev P (1988) Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci USA 85, 985989.
  • 69
    YeRD, Ahern SM, Le Beau MM, Lebo RV & Sadler JE (1989) Structure of the gene for human plasminogen activator inhibitor-2. The nearest mammalian homologue of chicken ovalbumin. J Biol Chem 264, 54955502.
  • 70
    Webb AC, Collins KL, Snyder SE, Alexander SJ, Rosenwasser LJ, Eddy RL, Shows TB & Auron PE (1987) Human monocyte Arg-Serpin cDNA. Sequence, chromosomal assignment, and homology to plasminogen activator-inhibitor. J Exp Med 166, 7794.
  • 71
    Pytel BA, Peppel K & Baglioni C (1990) Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumor necrosis factor. J Cell Physiol 144, 416422.
  • 72
    Sutter TR, Guzman K, Dold KM & Greenlee WF (1991) Targets for dioxin: genes for plasminogen activator inhibitor-2 and interleukin-1 beta. Science 254, 415418.
  • 73
    Bystrom J, Wynn TA, Domachowske JB & Rosenberg HF (2004) Gene microarray analysis reveals interleukin-5-dependent transcriptional targets in mouse bone marrow. Blood 103, 868877.
  • 74
    Camerer E, Gjernes E, Wiiger M, Pringle S & Prydz H (2000) Binding of factor VIIa to tissue factor on keratinocytes induces gene expression. J Biol Chem 275, 65806585.
  • 75
    Jang WG, Kim HS, Park KG, Park YB, Yoon KH, Han SW, Hur SH, Park KS & Lee IK (2004) Analysis of proteome and transcriptome of tumor necrosis factor alpha stimulated vascular smooth muscle cells with or without alpha lipoic acid. Proteomics 4, 33833393.
  • 76
    Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, Friedrich SO, Kostner GM & Schmitz G (2001) Lipoprotein(a) up-regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 97, 981986.
  • 77
    Cousin E, Medcalf RL, Bergonzelli GE & Kruithof EK (1991) Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator inhibitor type 2 gene promoter. Nucleic Acids Res 19, 38813886.
  • 78
    Kruithof EK & Cousin E (1988) Plasminogen activator inhibitor 2. Isolation and characterization of the promoter region of the gene. Biochem Biophys Res Commun 156, 383388.
  • 79
    Dear AE, Costa M & Medcalf RL (1997) Urokinase-mediated transactivation of the plasminogen activator inhibitor type 2 (PAI-2) gene promoter in HT-1080 cells utilises AP-1 binding sites and potentiates phorbol ester-mediated induction of endogenous PAI-2 mRNA. FEBS Lett 402, 265272.
  • 80
    Dear AE, Shen Y, Ruegg M & Medcalf RL (1996) Molecular mechanisms governing tumor-necrosis-factor-mediated regulation of plasminogen-activator inhibitor type-2 gene expression. Eur J Biochem 241, 93100.
  • 81
    Antalis TM, Costelloe E, Muddiman J, Ogbourne S & Donnan K (1996) Regulation of the plasminogen activator inhibitor type-2 gene in monocytes: localization of an upstream transcriptional silencer. Blood 88, 36863697.
  • 82
    Ogbourne SM & Antalis TM (2001) Characterisation of PAUSE-1, a powerful silencer in the human plasminogen activator inhibitor type 2 gene promoter. Nucl Acids Res 29, 39193927.
  • 83
    Medcalf RL, Van den Berg E & Schleuning WD (1988) Glucocorticoid-modulated gene expression of tissue- and urinary-type plasminogen activator and plasminogen activator inhibitor 1 and 2. J Cell Biol 106, 971978.
  • 84
    Medcalf RL (1992) Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid. Studies on the plasminogen activating system. J Biol Chem 267, 1222012226.
  • 85
    Maurer F & Medcalf RL (1996) Plasminogen activator inhibitor type 2 gene induction by tumor necrosis factor and phorbol ester involves transcriptional and post-transcriptional events. Identification of a functional nonameric AU-rich motif in the 3′-untranslated region. J Biol Chem 271, 2607426080.
  • 86
    Maurer F, Tierney M & Medcalf RL (1999) An AU-rich sequence in the 3′-UTR of plasminogen activator inhibitor type 2 (PAI-2) mRNA promotes PAI-2 mRNA decay and provides a binding site for nuclear HuR. Nucleic Acids Res 27, 16641673.
  • 87
    Yu H, Stasinopoulos S, Leedman P & Medcalf RL (2003) Inherent instability of plasminogen activator inhibitor type 2 mRNA is regulated by tristetraprolin. J Biol Chem 278, 1391213918.
  • 88
    Peng SS, Chen CY, Xu N & Shyu AB (1998) RNA stabilization by the AU-rich element binding protein, HuR, an ELAV protein. EMBO J 17, 34613470.
  • 89
    Carballo E, Lai WS & Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281, 10011005.
  • 90
    Stoecklin G, Ming XF, Looser R & Moroni C (2000) Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol 20, 37533763.
  • 91
    Tierney MJ & Medcalf RL (2001) Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 276, 1367513684.